Web-Mediated Risk Assessment for Endoscopic Screening of Gastric Cancer

Gastric Cancer Clinical Trial

Official title:

Randomized Trial Comparing Gastroscopy Following Web-Mediated Risk Assessment With Routine Endoscopy for Gastric Cancer Screening

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03484949
• Other study ID #: xjtu-20170816
• Status: Recruiting
• Phase: N/A
• First received: March 25, 2018
• Last updated: April 16, 2018
• Start date: December 1, 2017
• Est. completion date: December 1, 2020

Study information

• Verified date: April 2018
• Source: State Key Laboratory of Cancer Biology
• Contact: Dake Chu, M.D.
• Phone: 86-29-85323922
• Email: chudake[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Gastric cancer is one of the most common malignancies in China. Early detection is critical for gastric cancer management. However, the diagnosis rate of patients with early gastric cancer is still low. Therefore, the investigator design this study to access whether pre-endoscopic screening risk assessment of genetic and environmental risk factors could improve early gastric cancer diagnosis rate.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: December 1, 2020
• Est. primary completion date: December 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• 1.Age 18-60. 2.Signed informed consent

Exclusion Criteria:

• 1.Severe back ground disease including malignancy. 2.State after gastric surgery. 3.COPD, CHF, CRF and any disease with respiratory disturbances. 4.Deviation of the nasal septum, lack of venous access at the dorsum of the hand or any other technical problem prevents gastric acid collection or base excess evaluation.

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Intervention

Diagnostic Test:
• pre-endoscopic screening risk assessment
pre-endoscopic screening risk assessment

Locations

Country	Name	City	State
China	Dake Chu	Xi'an	Shaanxi

Sponsors (3)

Lead Sponsor	Collaborator
State Key Laboratory of Cancer Biology	Tang-Du Hospital, Xijing Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnostic rate of patients with early gastric cancer	Diagnostic rate of patients with early gastric cancer	2020
Secondary	Characterization of the high-rik individual for gastric cancer	Diagnostic rate of patients with early gastric cancer	2020